NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Enphase Energy, Inc. (NASDAQ: ENPH) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Enphase securities between April 22, 2025 and October 28, 2025, both ...

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health and future expenses following its IPO, leading to significant stock price declines [1][3][4]. Company Overview - Navan, Inc. operates an AI-powered software platform aimed at simplifying travel and expense management for users, customers, and suppliers [2]. IPO Details - Navan conducted its IPO on October 31, 2025, issuing nearly 37 million shares at an offering price of $25.00 per share [2]. Allegations of Misleading Information - The lawsuit claims that the IPO offering documents were materially false and omitted critical information, specifically that Navan would increase its sales and marketing expenses by 39% shortly after the IPO to maintain revenue growth [3]. Financial Performance and Stock Impact - On December 15, 2025, Navan reported a 39% increase in sales and marketing expenses, rising to nearly $95 million from $68.5 million in the previous quarter, which led to a nearly 12% drop in stock price [4]. - By the time the lawsuit commenced, Navan's stock price had fallen to as low as $9.20 per share, representing a nearly 63% decline from the IPO price [5]. Legal Process for Lead Plaintiff - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan stock during the IPO to seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6].

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025, b ...

Core观点 - Corcept Therapeutics Incorporated is facing a securities fraud class action lawsuit due to undisclosed concerns from the FDA regarding its drug relacorilant's effectiveness in treating hypertension in patients with hypercortisolism [1] 分组1 - The lawsuit alleges that between October 31, 2024, and December 30, 2025, Corcept failed to disclose critical information from the FDA [1] - The FDA expressed concerns about the adequacy of the program assessing relacorilant's effectiveness, including issues with the design of the pivotal "GRACE" trial study [1] - The FDA indicated that significant issues were expected during the review if Corcept submitted the New Drug Application (NDA) [1] 分组2 - As a result of these undisclosed issues, the positive statements made by Corcept regarding its business, operations, and prospects were deemed materially misleading [1] - Investors who suffered losses related to Corcept are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for April 21, 2026 [1]

Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company and its executives misled investors regarding the true drivers of its sales growth, which was primarily due to retailers hoarding inventory rather than genuine consumer demand [3][5]. Company Overview - BellRing Brands, Inc. is facing a securities fraud lawsuit that claims misleading statements were made about the sustainability and drivers of its sales growth, as well as the competitive landscape affecting demand for its products [5][6]. Sales Growth Misrepresentation - The lawsuit contends that the reported sales growth in 2025 was not reflective of actual consumer demand but was instead driven by retailers stockpiling inventory to mitigate previous supply chain shortages [3][7]. - Following the resolution of supply chain issues, retailers began to destock their excess inventory, leading to a significant drop in BellRing's sales and share price [7]. Market Reaction - On May 6, 2025, after disappointing Q2 results, BellRing's CFO acknowledged that some retailers had been hoarding inventory, which resulted in a 19% drop in share price [7]. - The Q3 2025 results, reported on August 4, 2025, revealed a narrowed sales outlook and increased competition, causing a further 33% decline in share price [7]. Legal Proceedings - The lead plaintiff deadline for the lawsuit is set for March 23, 2026, and investors who suffered losses from November 19, 2024, to August 4, 2025, are encouraged to participate [6][7].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares during the specified Class Period, highlighting potential misrepresentation regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Mereo securities from June 5, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Company Background - Mereo BioPharma is a biopharmaceutical company based in London, UK, focusing on therapies for rare and serious diseases [2]. Group 3: Clinical Trials and Impact - Throughout the Class Period, Mereo made positive statements regarding the ORBIT and COSMIC Phase 3 programs, which were clinical trials for setrusumab aimed at treating Osteogenesis Imperfecta [3]. - On December 29, 2025, Mereo disclosed that neither clinical trial achieved its primary endpoint, leading to a significant drop in the price of its ADS by over 87%, from $2.31 to $0.29 per share [4].

Core Viewpoint - Richtech Robotics Inc. is facing a class action lawsuit due to allegations of misleading investors about its relationship with Microsoft, which has resulted in significant stock price declines [1]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Diez v. Richtech Robotics Inc., and it involves investors who purchased Richtech Robotics securities between January 27, 2026, and January 29, 2026 [1]. - The lawsuit alleges that Richtech Robotics falsely claimed a commercial relationship with Microsoft, which was denied by Microsoft in a subsequent article published on January 29, 2026 [1]. - Following the publication of the article, Richtech Robotics Class B stock experienced a decline of over 29% within two trading days [1]. Group 2: Lead Plaintiff Process - Investors who acquired Richtech Robotics securities during the class period can seek to be appointed as lead plaintiff in the lawsuit [1]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and represents the interests of all class members [1]. - The lead plaintiff has the authority to select a law firm to litigate the case, and participation as lead plaintiff does not affect the ability of other investors to share in any potential recovery [1]. Group 3: Company Background - Richtech Robotics develops and sells robotic solutions aimed at automation in the service industry [1]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1].

Core Points - The CoreWeave class action lawsuit has been initiated against CoreWeave, Inc. and certain executives for alleged violations of the Securities Exchange Act of 1934 during the class period from March 28, 2025, to December 15, 2025 [1] - The lawsuit claims that CoreWeave overstated its ability to meet customer demand and failed to disclose significant risks associated with reliance on a single third-party data center supplier [3] - CoreWeave's stock price experienced significant declines following announcements related to merger agreements and lowered revenue guidance, indicating potential investor losses [4][5] Company Allegations - CoreWeave is positioned as an AI cloud computing company and announced a deal worth up to $11.9 billion with OpenAI shortly before its IPO [2] - The lawsuit alleges that CoreWeave's executives made misleading statements regarding the company's operational capabilities and the risks associated with its data center supplier [3] - A merger agreement with Core Scientific was terminated due to insufficient shareholder votes, leading to a more than 6% drop in CoreWeave's stock price [4] Revenue Guidance and Market Reaction - On November 10, 2025, CoreWeave lowered its revenue guidance for 2025, attributing the changes to delays from a third-party data center developer [5] - Following a CNBC interview where the CEO acknowledged broader implications of the delays, CoreWeave's stock fell by over 16% [5] - A December 15, 2025 article revealed further issues with data center delivery, causing an additional 3.4% decline in stock price [6]

Core Viewpoint - The Enphase Energy class action lawsuit alleges that the company and its executives made misleading statements regarding its financial and operational prospects, leading to significant stock price declines following the disclosure of poor financial results [3][4]. Group 1: Class Action Details - The class action lawsuit is titled Tripathi v. Enphase Energy, Inc., and it involves purchasers of Enphase Energy securities from April 22, 2025, to October 28, 2025 [1]. - Investors have until April 20, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Enphase Energy overstated its ability to manage channel inventory and mitigate the effects of the termination of the Residential Clean Energy Credit [3]. Group 2: Financial Implications - On October 28, 2025, Enphase Energy reported third-quarter financial results, indicating that elevated channel inventory would lead to lower battery storage shipments in the fourth quarter of 2025 [4]. - The expiration of the 25D Credit is expected to negatively impact revenues for the first quarter of 2026 [4]. - Following the announcement of these results, Enphase Energy's stock price fell by more than 15% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Enphase Energy securities during the class period to seek lead plaintiff status [5]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [5]. - An investor's potential recovery is not contingent upon serving as lead plaintiff [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 [6]. - The firm has ranked 1 in securities class action recoveries for four out of the last five years, totaling $8.4 billion in recoveries during that period [6].

Core Viewpoint - Nidec Corporation is under investigation for possible securities fraud, leading to significant stock price declines and potential class action lawsuits by investors [1][2]. Group 1: Stock Price Decline - On September 4, 2025, Nidec's stock price fell by $0.81, or 16.5%, closing at $4.11 per share after the company disclosed the establishment of a third-party committee to investigate improper accounting [2]. - Following further disclosures of suspected inappropriate accounting, shares fell an additional $0.29, or 6.6%, to close at $4.09 per share on September 26, 2025 [2]. - By October 23, 2025, the stock dropped $1.17, or 25.4%, to $3.43 after the company withdrew its year-end forecast and canceled a surplus dividend due to ongoing investigations [2]. - On October 27, 2025, the stock price fell $0.80, or 20.3%, closing at $3.15 per share after being placed under a Special Security alert by the Tokyo Stock Exchange [2]. Group 2: Investigation Details - The investigations revealed multiple documents suggesting that Nidec and its group companies may have engaged in improper accounting with management's involvement or knowledge [2]. - Specific issues included reporting customs values lower than appropriate without legitimate reasons and receiving an audit report with a disclaimer of opinion from its auditor [2]. - The Tokyo Stock Exchange noted deficiencies in Nidec's internal control systems, particularly regarding information, communication, and financial closing processes [2].